Fresenius Se & Co. Kgaa

BAD HOMBURG, Germany, November 2, 2011 - Q1-32011: Sales€12.1billion, +2% at actual rates, +5% in constant currency EBIT€1,862million, +5% at actual rates, +9% in constant currency Net income[1]€565 million, +14% at actual rates, +17% in constant currency Fresenius improves 2011 earnings[1] outlook of 15% to 18% constant currency growth to upper half of range Group earnings at single-quarter all-time high - €202 million net income[1], record 16% EBIT margin Fresenius Medical Care with further margin improvement and strong earnings growth Fresenius Kabi with 3% organic sales growth over outstanding Q3 2010 Fresenius Helios continues expansion in the German hospital market − raises earnings guidance Fresenius Vamed with excellent order intake of €171 million in Q3 Ulf Mark Schneider, CEO of Fresenius, commented: "Fresenius had a very strong third quarter.